Olga Kalinina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olga Kalinina has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Katherine L. Knight
Department of Microbiology and Immunology, Loyola University Chicago, Maywood, USA
2 shared publications Anne I Sperling
Pulmonary and Critical Care Division, Department of Medicine, University of Virginia , Charlottesville, VA
1 shared publication- Anne I. Sperling
Department of Medicine, University of Virginia, Charlottesville, VA, USA
1 shared publication Barbara A. Osborne
Department of Veterinary & Animal Sciences, University of Massachusetts, Amherst, Massachusetts; HasenTech, LLC, Leverett, Massachusetts
1 shared publicationJesus Zamora-Pineda
Department of Microbiology and Immunology, Loyola University Chicago , Maywood, IL
1 shared publication- Lisa M. Minter
Department of Veterinary and Animal Sciences, University of Massachusetts Amherst, Amherst, MA, United States
1 shared publication
Latest Publications
- Open Access
- 2 November 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (1) , 79.e1-79.e10
Exopolysaccharide-Treated Dendritic Cells Effectively Ameliorate Acute Graft-versus-Host Disease
- 2 November 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (1) , 79.e1-79.e10
Open AccessExopolysaccharide-Treated Dendritic Cells Effectively Ameliorate Acute Graft-versus-Host Disease
- 6 September 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 211 (8) , 1232-1239
Mechanism of TLR4-Mediated Anti-Inflammatory Response Induced by Exopolysaccharide from the Probiotic Bacillus subtilis
Intestinal inflammatory diseases affect millions of people worldwide, and one class of drugs showing promise toward treatment of several inflammatory diseases is probiotics. Numerous studies have been performed using probiotics to prevent and treat intestinal inflammatory diseases. Most of these studies used intact bacteria, and neither the active molecule nor the molecular mechanisms by which they affect immune responses are known. We have shown that the probiotic Bacillus subtilis is anti-inflammatory and can protect mice from acute colitis induced by the enteric pathogen Citrobacter rodentium. We identified and purified the active molecule, exopolysaccharide (EPS), and showed that it protects mice from C. rodentium–induced colitis by inducing anti-inflammatory M2 macrophages or inhibitory dendritic cells (DCs), both of which inhibit excessive T cell responses. We showed previously that EPS affects macrophages and DCs in a TLR4-dependent manner, and in the current study we asked how EPS induces these anti-inflammatory cells and how they function to inhibit T cells. By investigating the signaling downstream of TLR4 that leads to acquisition of inhibitory properties of macrophages and DCs, we found that EPS induces expression of the inhibitory molecule IDO in bone marrow–derived DCs, and that inhibition of T cell proliferation by IDO-expressing bone marrow–derived DCs utilizes the kynurenine/aryl hydrocarbon receptor circuit. Furthermore, unlike LPS, EPS does not induce inflammatory cytokines upon injection in vivo, directly demonstrating different outcomes induced by two different TLR4 agonists.
- 6 September 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 211 (8) , 1232-1239
Mechanism of TLR4-Mediated Anti-Inflammatory Response Induced by Exopolysaccharide from the Probiotic Bacillus subtilis
Intestinal inflammatory diseases affect millions of people worldwide, and one class of drugs showing promise toward treatment of several inflammatory diseases is probiotics. Numerous studies have been performed using probiotics to prevent and treat intestinal inflammatory diseases. Most of these studies used intact bacteria, and neither the active molecule nor the molecular mechanisms by which they affect immune responses are known. We have shown that the probiotic Bacillus subtilis is anti-inflammatory and can protect mice from acute colitis induced by the enteric pathogen Citrobacter rodentium. We identified and purified the active molecule, exopolysaccharide (EPS), and showed that it protects mice from C. rodentium–induced colitis by inducing anti-inflammatory M2 macrophages or inhibitory dendritic cells (DCs), both of which inhibit excessive T cell responses. We showed previously that EPS affects macrophages and DCs in a TLR4-dependent manner, and in the current study we asked how EPS induces these anti-inflammatory cells and how they function to inhibit T cells. By investigating the signaling downstream of TLR4 that leads to acquisition of inhibitory properties of macrophages and DCs, we found that EPS induces expression of the inhibitory molecule IDO in bone marrow–derived DCs, and that inhibition of T cell proliferation by IDO-expressing bone marrow–derived DCs utilizes the kynurenine/aryl hydrocarbon receptor circuit. Furthermore, unlike LPS, EPS does not induce inflammatory cytokines upon injection in vivo, directly demonstrating different outcomes induced by two different TLR4 agonists.